Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common indication for liver transplantation in the United States. Currently-available treatments are characterized by suboptimal tolerability and efficacy, resulting in a high unmet need for therapies that can be used to treat the broader HCV patient population.
This report focuses on current and future use of leading interferon-based regimens and Incivo/Victrelis-based triple therapy, patient market share, perceived strengths and weaknesses of the key brands, barriers to up-take, sales force performance, and perceived value of manufacturers’ patient assistance programs. Physician familiarity, interest, and potential impact of agents in development is also assessed.
Questions Answered in This Report:
What is the makeup of a physician’s HCV case load (by patient type/severity, patient origination, treatment experience, usage of antiviral treatment)?
How many patients are non-treated or “warehoused,” and how has this number changed following introduction of the protease inhibitors?
What are the current and anticipated patient shares for the approved treatments? What are the physician-perceived differences and preferences for Pegasys vs. PegIntron and the protease inhibitors?
How are current treatment practices and prescribing expected to shift in the next six months? What is driving and hindering product adop-tion and broader drug usage?
How important and effective are manufacturers’ patient assistance programs, company support programs, and promotional detailing ef-forts?
How interested are physicians in new products in development and how will new products impact the market?
Sample Frame & Methodology:
~100 gastroenterologists, hepatologists, and infectious disease special-ists complete a 45-minute online quantitative survey with several open-ended questions for qualitative feedback.
To qualify, respondents must meet the following criteria:
- Board certified in their specialty
- Minimum of 25 patients with HCV
- Have been in practice a minimum of 2 years and a maximum of 30 years
- More than 75 percent of professional time spent in clinical practice
- Not on a national advisory board for any of the profiled companies
Final report in PowerPoint format
Trending will be provided for clients purchasing relevant previous reports
Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request
Proprietary question slide deck: Clients purchasing report prior to fielding will have the opportunity to include up to three proprietary questions
2nd Quarter: May 2013
4th Quarter: November 2013
50 gastroenterologists, 25 hepatolo-gists, and 25 infectious disease specialists
Key Companies Mentioned:
Johnson & Johnson / Janssen
Key Drugs Covered:
Incivek (telaprevir), Victrelis (boceprevir), Pegasys (peg-IFN-?-2a), PegIntron (peg-IFN-?-2b ), and ribavirin, and products in late-stage development, including ABT-267, ABT-333, ABT-450, BI-207127, asunaprevir, daclatasvir, faldaprevir, ledipasvir simeprevir, and sofosbuvir
Related 2013 Reports:
- TreatmentTrends®: Hepatitis C Virus (EU)
- ChartTrends®: Hepatitis C Virus (US)
- LaunchTrends®: Sofosbuvir and Simeprevir (US)
- PatientTrends®: Hepatitis C Virus (US)
- Pharmacor®: Hepatitis C Virus
- DecisionBase®: Treatment-Naïve Hepatitis C Virus
- Physician & Payer Forum (EU)®: The Impending Interferon-Free Era of Hepatitis C Virus Treatment
- Emerging Markets®: Hepatitis C Virus in Turkey
- Physician & Payer Forum Emerging Markets®: Hepatitis C Virus in Brazil, Mexico, and Argentina